Immunotherapy in Eosinophilic Granulomatosis with Polyangiitis: A New Step Forward?

Xavier Puéchal

National Referral Center for Rare Systemic Autoimmune Diseases, Necrotizing Vasculitides, Department of Internal Medicine, Université Paris Descartes

Hôpital Cochin, Assistance Publique – Hôpitaux de Paris 27, rue du faubourg Saint Jacques, 75014 Paris, France

Corresponding author: Xavier Puéchal, National Referral Center for Rare Systemic Autoimmune Diseases, Necrotizing Vasculitides, Department of Internal Medicine, Université Paris Descartes and INSERM U1016, Cochin Institute, Paris, France. Tel: 33 1 58 41 32 41; Fax: 33 1 58 41 29 68; E-mail: xavier.puechal@aphp.fr

Received date: March 25, 2016; Accepted date: March 28, 2016; Published date: March 31, 2016

Copyright: © 2016 Puéchal X. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Editorial

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) [1]. EGPA has distinct features, namely asthma, common rhino-sinusal involvement, hyper eosinophilia, tissue infiltration with eosinophils and necrotizing granulomatous vasculitis [2-4].

Conventional immunosuppressive therapy and glucocorticoids have been GPA and MPA standard of care for remission induction and maintenance for four decades. This regimen has transformed the outcome from death to a strong likelihood of disease control and temporary remission. However, most patients have recurrent relapses that lead to damage and require repeated treatment. Cumulative side effects of immunosuppressive agents and glucocorticoids thus remain major causes of long-term morbidity, damage and death.

The development of therapeutic immunomodulation in systemic autoimmune diseases has shed new light on these complex diseases [5,6]. Rituximab, an anti-CD20 monoclonal antibody that depletes B-cells in peripheral blood, has been shown to be not inferior to cyclophosphamide to induce remission in GPA and MPA patients, with an acceptable safety profile, leading to its registration by the EMA and FDA as drug remission-induction therapy in these patients [7-9]. In addition the MAINRITSAN trial, conducted by the French Vasculitis Study Group, demonstrated that pre-emptive low dose rituximab given every 6 months for 18 months was significantly more effective than azathioprine standard of care to maintain remission in GPA and MPA, with a similar profile of tolerance [10]. Such therapeutic immunomodulation has changed the standard of care for maintenance therapy in these vasculitides.

Patients with EGPA were excluded from these pivotal trials because this vasculitis is rarer and positive ANCA tests are less frequent than in other ANCA-associated vasculitides. In a long-term analysis of randomized trials of 118 EGPA patients, we have reported that only 29% of patients achieved long-term remission and that relapses occurred in more than 40% of patients, leading to high cumulative morbidity and damage [3]. Moreover, most of these patients cannot be weaned of corticosteroids due to asthma and rhino-sinusal ongoing manifestations, even after vasculitis remission. Their long-term outcome remains to be improved.

Progress has been made in the assessment of EGPA vasculitis activity and of rhino-sinusal manifestations. The EULAR expert recommendations for definition of remission include a prednisone dose ≤ 7.5 mg/day [11]. It is now recognized in EGPA that ear, nose and throat (ENT) manifestations and/or asthma flares may not necessarily reflect vasculitis activity [2,3]. The EGPA Task Force recently proposed that the definition of remission in EGPA do not include the control of asthma and/or ENT manifestations [12]. These symptoms should be monitored separately and results should be given beside the evaluation of the vasculitis activity.

EGPA is classically considered a TH2-mediated disease with an activated and skewed T-cell balance [13]. EGPA patients T cells can produce high levels of TH2-associated cytokines such as IL-4 and IL-13 [14]. IL-5 is also up-regulated in active EGPA and is particularly essential for eosinophil activation, maturation and survival. However, the clinical phenotype cannot be explained by an isolated exaggerated TH2 response [4]. Th1 and Th17 cells are also implicated and secrete high amounts of IL-17A in the late phases of the disease [4,14]. Moreover, several lines of evidence also point to a role of B lymphocytes and humoral responses as further contributing to EGPA pathogenesis. Increase in the levels of activated and memory B cells have been found in active EGPA [15]. Myeloperoxidase (MPO)-pANCA are present in 40% of untreated patients [2]. Patients with EGPA flares often had increased levels of total serum IgE and IgE-containing immune complexes [16], initially supported the hypothesis that EGPA might be an allergy-induced, immune-complex vasculitis. Elevated serum IgG4 have also been common features and the switch towards IgG4 production is related to the inflammatory milieu conditioning B-cell maturation, and particularly to the presence of TH2 cytokines such as IL4, IL5 and IL13 [17].

Furthermore, recent case reports and small retrospective series [18-25] have indicated that rituximab may also be an effective remission induction agent in refractory or relapsing EGPA. A review of published series of rituximab for EGPA patients is shown in Table 1. A total of 73 EGPA patients who had received rituximab, mainly for refractory or relapsing disease, have been compiled in a recent analysis [26]. Efficacy of rituximab therapy was significant in the vast majority of cases and in a wide variety of disease manifestations. The largest series to date has reported 41 EGPA patients, who received rituximab in four expert vasculitis centers, mostly for refractory or relapsing disease [24]. Patients with positive ANCA testing were significantly more likely to achieve remission at 12 months: 80% (12/15) who were ANCA-positive versus 36% (8/21) who were ANCA-negative. In contrast, Thiel et al. have reported in 9 patients, that rituximab appeared to be an efficient and safe treatment for both ANCA-positive and ANCA-negative patients [23], as also mentioned by Novikov et al [25]. Largest prospective studies will have to clarify this issue.
Complications which may be severe in these immunocompromised patients include worsening of asthma in one [24]. Severe bronchospasm has already been reported during the first 15 minutes of rituximab infusions in two EGPA patients [20]. In addition, very few patients also received rituximab as maintenance therapy in EGPA to prevent relapses. In a study, preemptive retreatment with rituximab in three patients, combined with standard maintenance immunosuppressant resulted in a sustained treatment response with a median follow-up of 3 years [23].

The mechanisms by which an anti-CD20 therapy might be efficient in EGPA remain unclear. It has been hypothesized that activated B cells may contribute to mechanisms of tissue injury as antigen-presenting cells, regulating the development of T cells by expressing costimulatory molecules, and as precursors to plasma cells, giving rise to eosinophilia [22].

### Table 1: Rituximab for treatment of eosinophilic granulomatosis with polyangiitis.

| Authors [reference] | Year | Design | Number | ANCA | RTX dosing | Outcome | Severe adverse events | Median duration follow-up (months) | Mean prednisone dose decrease (mg/day) | RTX retreatment |
|---------------------|------|--------|--------|------|------------|---------|----------------------|-------------------------------------|--------------------------------------|-----------------|
| Koukoulaki [18]     | 2006 | Retrospective report | 2      | None (N=1); NA (N=1) | 375 mg/m² weekly x 4 (N=1); 1g, 2 weeks apart (N=1) | Remission: 2/2 | Respiratory tract infection (N=1) | 16.5 | 12.5 => 4.5 | One patient required repeated RTX infusions at M7 and M16 due to nasal and asthma flare with eosinophilia |
| Pepper [19]         | 2008 | Retrospective report | 2      | Anti-MPO (N=1); Anti-PR3 (N=1) | 1g, 2 weeks apart (N=1); 375 mg/m² weekly x 4 (N=1) | Remission: 2/2 | None reported | 6 | NA | None |
| Boudouyre [20]      | 2009 | Retrospective report | 2      | None | 375 mg/m² (N=2) | NA | Severe bronchospasm during infusion (N=2) | NA | NA | RTX was withdrawn |
| Donvik [21]         | 2011 | Retrospective report | 2      | None | 1g, 2 weeks apart (N=2) | Remission: 2/2 | None reported | 12.5 | NA | Preemptive RTX retreatment for 6 and 18 months, for one patient each |
| Cartin-Ceba [22]    | 2011 | Prospective open-label pilot study | 3      | Anti-MPO (N=3) | 375 mg/m² weekly x 4 (N=3) | Remission M12: 3/3 | None related to RTX | 12 | 50 => 3.3 | One patient had successful repeated RTX infusions at M6 for a vasculitis relapse |
| Thiel [23]          | 2013 | Retrospective report | 9      | Anti-MPO (N=5) | 1g, 2 weeks apart (N=9) | Remission M9: 6/9 | None related to RTX | 9 | 15 => 7.5 | Preemptive RTX retreatment in 3 patients resulted in a sustained response with a median follow-up of 3 years |
| Mohammad [24]       | 2016 | Retrospective report | 41     | Anti-MPO (N=9); Anti-PR3 (N=4) | 375 mg/m² weekly x 4 (N=10); 1g, 2 weeks apart (N=30); 0.8g, 2 weeks apart (N=1) | Remission M12: ANCA+: 80%; ANCA–: 38% | 10 in 21 patients after a total of 79 RTX courses within one year: infection (N=6); infection reaction (N=2); other (N=2) | 12 | 15 => 8 | Relapse in 4 patients at M12; Preemptive RTX retreatment in 22 patients |
| Novikov [25]        | 2016 | Retrospective report | 6      | Anti-MPO (N=3); Anti-PR3 (N=1) | 0.5 g weekly x 4 (N=3); 1g, 2 weeks apart (N=1); 0.5g, 2 weeks apart (N=2) | Remission M6: 4/6 | Severe bronchospasm during infusion (N=1); infection (N=2) | 10 | 35 => 8.75 | Preemptive RTX retreatment in one patient resulted in a sustained response with a median follow-up of 3.5 years |

In the study reported by Mohammad et al., type and rate of response did not differ between the patients treated with rituximab 375 mg/m² for 4 weeks or with two doses of 1g given two weeks apart [24], as already shown in a retrospective study of patients with ANCA-associated vasculitis, of whom 5 had EGPA [27]. Apart infectious complications which may be severe in these immunocompromised patients already receiving glucocorticoids, other safety issues included infusion reactions in two patients requiring intubation due to worsening of asthma in one [24]. Severe bronchospasm has already been reported during the first 15 minutes of rituximab infusions in two EGPA patients [20]. In addition, very few patients also received
to MPO ANCA pathogenic autoantibodies. It has also been shown that rituximab mediates its beneficial actions in EGPA, at least in part, through the inhibition of T-cell IL-5 production [19]. It is interesting to note that Novikov et al. reported that all patients had improvement in their asthmatic symptoms [25].

The French Vasculitis Study Group recommended that rituximab can be prescribed to some EGPA patients whose disease is refractory to immunosuppressive therapy and responded only to high-dose corticosteroids, particularly forms characterized by predominant vascular disease (extracapillary glomerulonephritis, alveolar hemorrhage) and the presence of anti-MPO ANCA [28].

All these promising results obtained with rituximab should be confirmed in prospective randomized controlled trials to confirm the benefit of rituximab and define the safety profile in EGPA patients. REOVAS is a randomized controlled trial which is being implemented in EGPA patients to evaluate rituximab induction therapy as compared with standard of care. This trial of the French Vasculitis Study Group will include 108 patients. Its primary objective is to determine the efficacy of rituximab and glucocorticoids to induce a complete remission, defined as a Birmingham Vasculitis Activity Score of 0 and a prednisone dose ≤7.5 mg/day at day 180, in patients with newly-diagnosed or relapsing EGPA. The MAINRITSEG trial also designed by the French Vasculitis Study Group will assess whether therapeutic immunomodulation with rituximab may be an effective maintenance treatment.

Mepolizumab, a humanized monoclonal antibody against IL-5, has also generated promising results in eosinophilic asthma [29-32] and EGPA [33,34]. Two pilot studies with mepolizumab in EGPA have reported a corticosteroid sparing effect and remission maintenance in the absence of further conventional immunosuppressants [33,34]. A large randomized, double-blind, phase III study is currently investigating the efficacy and safety of mepolizumab compared with placebo in subjects with relapsing or refractory EGPA receiving standard of care therapy including background corticosteroid therapy with or without immunosuppressive therapy (MIRRA, ClinicalTrials.gov Identifier: NCT02020889).

Other therapeutic immunomodulation are being evaluated in EGPA. The introduction of anti-IgE therapy for asthma inaugurated the era of biological therapies and has been shown to be useful for patients with allergic severe asthma [35,36]. EGPA patients have also been treated with omalizumab with conflicting results [37,38], some patients presenting vasculitis onset after omalizumab therapy [39,40]. As now accepted with leukotriene antagonists, it is likely that omalizumab may have unmasked a preexisting vasculitis in some cases but additional data are necessary before concluding that omalizumab has no role in these complications.

In conclusion, there remains a major unmet need in patients with EGPA for safer therapy that leads to sustained remission, in order to reduce cumulative damage, morbidity and drug toxicity. The utility of rituximab and mepolizumab for the treatment of EGPA remains unproven, but initial reports of their efficacy/safety have provided a rationale for further studies. The ongoing randomized controlled trials with rituximab and mepolizumab are a new step forward in EGPA both as an induction and maintenance therapy. They will also have to evaluate these immunomodulating agents in terms of steroid sparing, damage and quality of life.

References

1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, et al. (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum;65: 1-11.
2. Comarmond C, Pagnoux C, Khelfaï M (2013) Eosinophilic granulomatosis with polyangitis (Churg-Strauss): clinical characteristics and long-term follow-up of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum;65:270-281.
3. Samson M, Puéchal X, Devilliers H, Ribi C, Cohen P, et al. (2013) Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun 43: 60-69.
4. Greco A, Rizzo MI, De Virgilio A, Gallo A, Fusconi M, et al. (2015) Churg- Strauss syndrome. Autoimmun Rev 14: 341-348.
5. Puéchal X, Guillemin I. (2013) Therapeutic immunomodulation in systemic vasculitis: taking stock. Joint Bone Spine 80: 374-379.
6. Puéchal X (2016) Therapeutic immunomodulation in eosinophilic granulomatosis with polyangitis (Churg-Strauss). Joint Bone Spine 83: 7-10.
7. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, et al. (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363: 211-220.
8. Stone JH, Merkal PA, Spiera R, Seo P, Langford CA, et al. (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221-232.
9. Specks U, Merkal PA, Seo P, Spiera R, Langford CA, et al. (2013) Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369: 417-427.
10. Guillemin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, et al. (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371: 1771-1780.
11. Groh M, Pagnoux C, Baldini C, Bel E, Bottiero P, et al. (2015) Eosinophilic granulomatosis with polyangitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 26: 545-553.
12. Hellmich B, Flossmann O, Gross WL (2007) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis;66: 605-617.
13. Vaglio A, Buzio C, Zwerina J (2013) Eosinophilic granulomatosis with polyangitis (Churg-Strauss): state of the art. Allergy 68: 261-273.
14. Kiene M, Csernok E, Müller A, Metzler C, Trabandt A, et al. (2001) Gross A, Flossmann O, Gross WL (2007) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis;66: 605-617.
15. Vaglio A, Buzio C, Zwerina J (2013) Eosinophilic granulomatosis with polyangitis (Churg-Strauss): state of the art. Allergy 68: 261-273.
16. Vaglio A, Buzio C, Zwerina J (2013) Eosinophilic granulomatosis with polyangitis (Churg-Strauss): state of the art. Allergy 68: 261-273.
17. Vaglio A, Strehl JD, Manger BJ, Maritati F, Alberici F, et al. (2012) IgG4 immune response in Churg-Strauss syndrome. Ann Rheum Dis;71: 390-393.
18. Kousoulaki M, Smith KG, Jayne DR (2006) Rituximab in Churg-Strauss syndrome. Ann Rheum Dis;65: 390-393.
19. Pepper RJ, Fabre MA, Pavesio C, Gaskin G, Jones RB, et al. (2008) Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 47: 1104-1105.
20. Bouldouyre MA, Cohen P, Guillemin I. (2009) Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome. Ann Rheum Dis;68: 606.

J Vasc
ISSN:2471-9544 JOV, an open access journal

Volume 2 • Issue 1 • 1000e106

Citation: Puéchal X (2016) Immunotherapy in Eosinophilic Granulomatosis with Polyangitis: A New Step Forward?. J Vasc 2: e106. doi: 10.4172/2471-9544.1000e106

Page 3 of 4
21. Dønvik KK, Omdal R (2011) Churg-Strauss syndrome successfully treated with rituximab. Rheumatol Int 31: 89-91.
22. Cartin-Ceba R, Keogh KA, Specks U, Sethi S, Fervenza FC, et al. (2011) Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant 26: 2865-2871.
23. Thiel J, Hässler F, Salzer U, Voll RE, Venhoff N, et al. (2013) Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res Ther 15(5):R133.
24. Mohammad AJ, Hot A, Arndt F, Moosig F, Guerry MJ, et al. (2016) Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis 75: 396-401.
25. Novikov P, Moiseev S, Smitienko I, Zagvozdkina E (2016) Rituximab as induction therapy in relapsing eosinophilic granulomatosis with polyangiitis: A report of 6 cases. Joint Bone Spine 83: 81-84.
26. Fanouriakis A, Kougkas N, Vassilopoulos D, Fragouli E, Repa A, et al. (2015) Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy: Case report and review of current clinical evidence. Semin Arthritis Rheum 45:60-66.
27. Jones RB, Ferraro AJ, Chaudhry AN (2009) A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum; 60: 2156-2168.
28. Charles P, Bienvenu B, Bonnotte B (2013) Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. Presse Med; 42: 1317-1330.
29. Nair P, Pizichini MM, Karsgaard M, Inman MD, Efthimiadis A, et al. (2009) Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 360: 985-993.
30. Pavord ID, Korn S, Howarth P, Bleecker ER, Buh R, et al. (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380: 651-659.
31. Bel EH, Wenzel SE, Thompson PJ, Praza CM, Keene ON, et al. (2014) Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371: 1189-1197.
32. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, et al. (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371: 1198-1207.
33. Kim S, Marigowda G, Oren E, Israel E, Wechsler ME, et al. (2010) Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 125: 1336-1343.
34. Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich R, et al. (2011) Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 155: 341-343.
35. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, et al. (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108: 184-190.
36. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, et al. (2011) Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 364: 1005-1015.
37. Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L (2009) Churg-Strauss syndrome in patients treated with omalizumab. Chest 136: 507-518.
38. Jackiet M, Samson M, Cottin V (2016) Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Data from 17 patients. Arthritis Rheumatol.
39. Winchester DE, Jacob A, Murphy T (2006) Omalizumab for asthma. N Engl J Med 355: 1281-1282.
40. Puéchal X, Rivereau P, Vinchon F (2008) Churg-Strauss syndrome associated with omalizumab. Eur J Intern Med 19: 364-366.